How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,065 results for

Mood Disorder

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Accelerated Resolution Therapy for Post-Traumatic Stress Disorder, Anxiety Disorders, or Mood Disorders: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Accelerated Resolution Therapy for Post-Traumatic Stress Disorder, Anxiety Disorders, or Mood Disorders: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Accelerated Resolution Therapy for Post-Traumatic Stress Disorder, Anxiety Disorders, or Mood Disorders: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Accelerated Resolution Therapy for Post-Traumatic Stress Disorder, Anxiety Disorders, or Mood Disorders: Clinical Effectiveness (...) , Cost-Effectiveness, and Guidelines Accelerated Resolution Therapy for Post-Traumatic Stress Disorder, Anxiety Disorders, or Mood Disorders: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: September 19, 2019 Project Number: RB1404-000 Product Line: Research Type: Non-Pharma Mental Health Intervention Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of Accelerated Resolution Therapy (ART) for the treatment of adults with post

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder Full Text available with Trip Pro

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar (...) on experience, and consensus ratings of safety, tolerability, and treatment-emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second- line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence-based treatment decisions. Lithium, quetiapine, divalproex, asenapine

2018 CPG Infobase

3. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary Gin S Malhi, Tim Outhred, Grace Morris, Philip M Boyce, Richard Bryant, Paul B Fitzgerald, Malcolm J Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Richard J Porter, Ajeet B Singh and Kristina Fritz Med J Aust 2018

2018 MJA Clinical Guidelines

4. Group Cognitive Processing Therapy for Adults with Post-Traumatic Stress Disorder, Anxiety, or Mood Disorders: A Review of Clinical Effectiveness and Guidelines

Group Cognitive Processing Therapy for Adults with Post-Traumatic Stress Disorder, Anxiety, or Mood Disorders: A Review of Clinical Effectiveness and Guidelines Group Cognitive Processing Therapy for Adults with Post-Traumatic Stress Disorder, Anxiety, or Mood Disorders: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Group Cognitive Processing Therapy for Adults with Post-Traumatic Stress Disorder, Anxiety, or Mood Disorders: A Review of Clinical (...) Effectiveness and Guidelines Group Cognitive Processing Therapy for Adults with Post-Traumatic Stress Disorder, Anxiety, or Mood Disorders: A Review of Clinical Effectiveness and Guidelines Published on: June 12, 2017 Project Number: RC0891-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of group cognitive processing therapy for adults with post-traumatic stress disorder, anxiety disorders

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Neurofeedback for Mood and Anxiety Disorders: Clinical Effectiveness

Neurofeedback for Mood and Anxiety Disorders: Clinical Effectiveness Neurofeedback for Mood and Anxiety Disorders: Clinical Effectiveness | CADTH.ca Find the information you need Neurofeedback for Mood and Anxiety Disorders: Clinical Effectiveness Neurofeedback for Mood and Anxiety Disorders: Clinical Effectiveness Last updated: February 28, 2018 Project Number: RB1198-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What (...) is the comparative clinical effectiveness of dynamical neurofeedback versus neurofeedback for mood or anxiety disorders in adults? What is the clinical effectiveness of telehealth-delivered neurofeedback for mood or anxiety disorders in adults? What is the clinical effectiveness of neurofeedback for the families of patients receiving neurofeedback for mood or anxiety disorders? Key Message No relevant literature was identified regarding the comparative clinical effectiveness of dynamical neurofeedback versus

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary Gin S Malhi, Tim Outhred, Amber Hamilton, Philip M Boyce, Richard Bryant, Paul B Fitzgerald, Bill Lyndon, Roger Mulder, Greg Murray, Richard J Porter, Ajeet B Singh and Kristina Fritz Med J Aust 2018; 208 (4

2018 MJA Clinical Guidelines

7. Association of Comorbid Mood and Anxiety Disorders With Autism Spectrum Disorder (Abstract)

Association of Comorbid Mood and Anxiety Disorders With Autism Spectrum Disorder It is critical to evaluate the risk of comorbid psychiatric diagnoses to meet the needs of individuals with autism spectrum disorder (ASD).To examine whether individuals with ASD are at greater risk for comorbid diagnoses of depression, anxiety, or bipolar disorder.This cohort study used data from a population-based birth cohort of 31 220 individuals born in Olmsted County, Minnesota, from January 1, 1976 (...) , to December 31, 2000. Patients with research-identified ASD were previously identified using a multistep process that evaluated signs and symptoms abstracted from medical and educational records. For each of the 1014 patients with ASD, 2 age- and sex-matched referents who did not meet criteria for ASD were randomly selected from the birth cohort (n = 2028). Diagnosis codes for anxiety, depression, and bipolar disorders were electronically obtained using the Rochester Epidemiological Project records

2020 EvidenceUpdates

8. Neurofeedback and Biofeedback for Mood and Anxiety Disorders: A Review of Clinical Effectiveness and Guidelines

Neurofeedback and Biofeedback for Mood and Anxiety Disorders: A Review of Clinical Effectiveness and Guidelines Neurofeedback and Biofeedback for Mood and Anxiety Disorders: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Neurofeedback and Biofeedback for Mood and Anxiety Disorders: A Review of Clinical Effectiveness and Guidelines Neurofeedback and Biofeedback for Mood and Anxiety Disorders: A Review of Clinical Effectiveness and Guidelines Published (...) on: November 13, 2017 Project Number: RC0939-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of neurofeedback provided by a health professional for mood or anxiety disorders in adults? What is the clinical effectiveness of biofeedback provided by a health professional for mood or anxiety disorders in adults? What is the clinical effectiveness of biofeedback using home equipment for mood

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. CRACKCast E111 – Mood Disorders

functioning or social activities or to necessitate hospitalization to prevent harm to self or others, or psychotic features are present. D. Symptoms are not caused by direct physiologic effects of a substance (eg, drug of abuse, medication) or a general medical condition (eg, hyperthyroidism). Modified from American Psychiatric Association [6] List 8 general medical conditions and 8 medications that cause depression/mood disorders. Medical Conditions Degenerative : Parkinson’s disease CAD MI Stroke End (...) Depressive Episode. Coles notes: A change from baseline, with 2 weeks of daily depressed mood or loss of interest/pleasure and at least 5 of the SIGE CAPS items Impaired social/job function Not caused by a medical condition or drug ingestion Not explained by another mental health disorder No history of mania BOX 101.1 (9th Ed.) Summary of DSM-V Criteria for a Major Depressive Episode A. Five or more of the following symptoms have been present almost every day during the same 2-week period and represent

2017 CandiEM

10. Cohort Study: Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder

Cohort Study: Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) in patients diagnosed with bipolar affective disorder Article Text Aetiology/Harm Cohort Study Adverse events associated with mood stabiliser treatment should be continuously monitored in patients diagnosed with bipolar affective disorder R E Nielsen 1 , 2 , R W Licht 3 Statistics from Altmetric.com Commentary on: Hayes JF , Marston L , Walters K , et al . Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort

2017 Evidence-Based Medicine

11. Mood Zoom could be a promising tool for daily mood variability monitoring, potentially differentiating bipolar from borderline patients

' diagnoses and symptoms largely rely on their autobiographical memory, ability to reflect and verbalise their inner experience and behaviour, and the interviewers' ability to conceptualise these communications. Reliable biomarkers for purposes of diagnosis and follow-up of illness course and treatment effectiveness are constantly sought. Both clinical experience and longitudinal research on mood variability among patients with mood disorders indicate a need for improved methods for patient monitoring (...) . Pioneering online mood charting tools 1 have existed for over a decade. Accumulating studies have already demonstrated that smartphone data can serve as an electronic biomarker of illness activity in bipolar disorder (BD). 2–4 However, studies comparing … Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content

2018 Evidence-Based Mental Health

12. Mood Prediction of Patients With Mood Disorders by Machine Learning Using Passive Digital Phenotypes Based on the Circadian Rhythm: Prospective Observational Cohort Study. Full Text available with Trip Pro

Mood Prediction of Patients With Mood Disorders by Machine Learning Using Passive Digital Phenotypes Based on the Circadian Rhythm: Prospective Observational Cohort Study. Virtually, all organisms on Earth have their own circadian rhythm, and humans are no exception. Circadian rhythms are associated with various human states, especially mood disorders, and disturbance of the circadian rhythm is known to be very closely related. Attempts have also been made to derive clinical implications (...) associated with mood disorders using the vast amounts of digital log that is acquired by digital technologies develop and using computational analysis techniques.This study was conducted to evaluate the mood state or episode, activity, sleep, light exposure, and heart rate during a period of about 2 years by acquiring various digital log data through wearable devices and smartphone apps as well as conventional clinical assessments. We investigated a mood prediction algorithm developed with machine

2019 Journal of medical Internet research

13. Addendum to the Acknowledgements: Mood Prediction of Patients With Mood Disorders by Machine Learning Using Passive Digital Phenotypes Based on the Circadian Rhythm: Prospective Observational Cohort Study. Full Text available with Trip Pro

Addendum to the Acknowledgements: Mood Prediction of Patients With Mood Disorders by Machine Learning Using Passive Digital Phenotypes Based on the Circadian Rhythm: Prospective Observational Cohort Study. [This corrects the article DOI: 10.2196/11029.].©Chul-Hyun Cho, Taek Lee, Min-Gwan Kim, Hoh Peter In, Leen Kim, Heon-Jeong Lee. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 03.10.2019.

2019 Journal of medical Internet research

14. Brain structural correlates of familial risk for mental illness: a meta-analysis of voxel-based morphometry studies in relatives of patients with psychotic or mood disorders. (Abstract)

Brain structural correlates of familial risk for mental illness: a meta-analysis of voxel-based morphometry studies in relatives of patients with psychotic or mood disorders. Schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD) are heritable psychiatric disorders with partially overlapping genetic liability. Shared and disorder-specific neurobiological abnormalities associated with familial risk for developing mental illnesses are largely unknown. We performed a meta (...) versus HC, and between those of each psychiatric disorder and HC. As a group, relatives exhibited gray matter abnormalities in left supramarginal gyrus, right striatum, right inferior frontal gyrus, left thalamus, bilateral insula, right cerebellum, and right superior frontal gyrus, compared with HC. Decreased right cerebellar gray matter was the only abnormality common to relatives of all three conditions. Subgroup analyses showed disorder-specific gray matter abnormalities in left thalamus

2020 Neuropsychopharmacology

15. Current status of electroconvulsive therapy for mood disorders: a clinical review

Current status of electroconvulsive therapy for mood disorders: a clinical review Current status of electroconvulsive therapy for mood disorders: a clinical review | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current status of electroconvulsive therapy for mood disorders: a clinical review Article Text Clinical review Current status of electroconvulsive therapy for mood disorders: a clinical review Dusan Kolar Statistics from

2017 Evidence-Based Mental Health

16. Psychotic disorders cause the greatest mortality disparity among mental disorders, though more deaths are attributable overall to mood and anxiety disorders

disorders, though more deaths are attributable overall to mood and anxiety disorders Article Text Outcomes Psychotic disorders cause the greatest mortality disparity among mental disorders, though more deaths are attributable overall to mood and anxiety disorders Daniel W Bradford , Natasha Cunningham Statistics from Altmetric.com ABSTRACT FROM: Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry (...) Psychotic disorders cause the greatest mortality disparity among mental disorders, though more deaths are attributable overall to mood and anxiety disorders Psychotic disorders cause the greatest mortality disparity among mental disorders, though more deaths are attributable overall to mood and anxiety disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time

2016 Evidence-Based Mental Health

17. Retinal function anomalies in young offspring at genetic risk of schizophrenia and mood disorder: The meaning for the illness pathophysiology. (Abstract)

Retinal function anomalies in young offspring at genetic risk of schizophrenia and mood disorder: The meaning for the illness pathophysiology. Visual defects are documented in psychiatric disorders such as schizophrenia, bipolar disorder and major depressive disorder. One of the most consistent alterations in patients is a change in cone and rod electroretinographic (ERG) responses. We previously showed a reduced rod b-wave amplitude in a small sample of young offspring born to an affected (...) parent. A confirmation of the patients ERG anomalies in young offspring at high genetic risk would offer a new approach to the neurodevelopmental investigation of the illness. We thus investigated cone and rod responses in a larger sample of young healthy high-risk offspring.The ERG was recorded in 99 offspring of patients having DMS-IV schizophrenia, bipolar or major depressive disorder (mean age 16.03; SD 6.14) and in 223 healthy controls balanced for sex and age. The a- and b-wave latency

2019 Schizophrenia Research

18. White Matter Microstructure in Pediatric Bipolar Disorder and Disruptive Mood Dysregulation Disorder. (Abstract)

White Matter Microstructure in Pediatric Bipolar Disorder and Disruptive Mood Dysregulation Disorder. Disruptive mood dysregulation disorder (DMDD) codifies severe, chronic irritability. Youth with bipolar disorder (BD) also present with irritability, but with an episodic course. To date, it is not clear whether aberrant white matter microstructure - a well-replicated finding in BD - can be observed in DMDD and relates to symptoms of irritability.We acquired DTI data from 118 participants (BD

2019 Journal of the American Academy of Child and Adolescent Psychiatry

19. The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. (Abstract)

The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. A large body of evidence has demonstrated that exposure to childhood maltreatment at any stage of development can have long-lasting consequences. It is associated with a marked increase in risk for psychiatric and medical disorders. This review summarizes the literature investigating the effects of childhood maltreatment on disease vulnerability (...) for mood disorders, specifically summarizing cross-sectional and more recent longitudinal studies demonstrating that childhood maltreatment is more prevalent and is associated with increased risk for first mood episode, episode recurrence, greater comorbidities, and increased risk for suicidal ideation and attempts in individuals with mood disorders. It summarizes the persistent alterations associated with childhood maltreatment, including alterations in the hypothalamic-pituitary-adrenal axis

2019 American Journal of Psychiatry

20. Effect of istradefylline on mood disorders in Parkinson's disease. (Abstract)

Effect of istradefylline on mood disorders in Parkinson's disease. Depression is the most common psychiatric complication in patients with Parkinson's disease (PD). Istradefylline, a new anti-parkinsonian agent with completely different mechanism, improves depression-like symptoms in an experimental disease model; however, there is no report of its effects in PD patients. In this study, the effectiveness of istradefylline for treatment of mood disorders in patients with PD was examined (...) every 2-4 weeks until 12 weeks and the changes in these scores were analyzed. Following administration of istradefylline, the scores of SHAPS-J, Apathy scale, and BDI were significantly improved over time. Significant improvement was also found in the UPDRS score; however, no significant correlation was observed between the score change in these 3 batteries and UPDRS motor function. This is the first study to show the effectiveness of istradefylline for treatment of mood disorders in PD independent

2019 Journal of the neurological sciences

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>